血清胸苷激酶1评估非小细胞肺癌化疗疗效的意义

Clinical significance of serum TK1 levels for patients with non-small-cell lung cancer undergoing chemotherapy

目的:探究血清胸苷激酶1(STK1)水平在非小细胞肺癌(NSCLC)患者4个周期化疗过程中的变化及其临床意义。方法:应用免疫印迹增强化学发光法检测59例NSCLC患者化疗前及第1、2、3、4周期化疗后STK1浓度,并分析其与化疗疗效间相关性。结果:4个周期化疗后,不同化疗方案间STK1水平无统计学差异。在化疗有效组,4个周期化疗后STK1水平较化疗前均显著下降;4个周期化疗后,有效组STK1均显著低于无效组;在有效组,第3、4周期化疗后STK1阳性率显著低于化疗前;化疗前及4个周期化疗后,STK1水平在肺鳞癌与肺腺癌间无统计学差异。结论 :NSCLC患者化疗过程中监测STK1水平的变化,有助于评估患者化疗疗效,并对后续治疗提供指导。

Objective To investigate the dynamic change and its clinical significance of serum thymidine kinase 1 （STK1） in patients with non-small-cell lung cancer （NSCLC） when undergoing 4 cycles of chemotherapy. Methods We detected STK1 levels of 59 patients with NSCLC throughout 4 cycles of chemotherapy using Enhanced Chemil Western Blot and analyze its relationship with chemotherapy responses Results STK1 levels with different chemotherapy regimens had no significant difference. STKK1 levels in patients with effective response were significantly lower after 4 cycles of chemotherapy. STK1 levels in patients with effective response were significantly lower than those in non-responders throughout 4 cycles of chemotherapy. The positive rates of STK1 in those with effective response were lower than those in non-responders after the last two cycles of chemotherapy. STK1 levels between lung squamous carcinoma and lung adenocarcinoma had no significant difference. Conclusion The detection of the changes of serum TK1 in patients with NSCLC undergoing chemotherapy is useful in evaluating the effect of chemotherapy and the later therapeutic schedule.